Update on the use of alitretinoin in treating chronic hand eczema

Clinical, Cosmetic and Investigational Dermatology

Volumn 3, Issue , 2010, Pages 59-65

  Ghasri, Pedram ^a   Scheinfeld, Noah ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

9 cisretinoic acid; Alitretinoin; Hand eczema

Indexed keywords

ALITRETINOIN; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PLACEBO; TOCTINO; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CHRONIC DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; ECONOMIC ASPECT; FLUSHING; HAND ECZEMA; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCIURIA; HYPERLIPIDEMIA; IMMUNOMODULATION; KAPOSI SARCOMA; NONHUMAN; PANCREATITIS; PHOTOTHERAPY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN DISEASE; SOCIAL ASPECT;

EID: 77953433343     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Coenraads PJ, Nater JP, van der Lende R. Prevalence of eczema and other dermatoses of the hands and arms in the Netherlands. Association with age and occupation. Clin Exp Dermatol. 1983;8(5):495-503.
2. Fowler JF, Duh MS, Chang J, et al. A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization. Cutis. 2006;77(6):385-392.
3. Diepgen TL, Agner T, Aberer W, et al. Management of chronic hand eczema. Contact Dermatitis. 2007;57(4):203-210.
4. Holden C, Berth-Jones J, Burns T, Breathnach S, Cox N, Griffiths C. Rook's Textbook of Dermatology; 2004.
5. McFadden J. Hand eczema. Textbook of Contact Dermatitis. 3rd ed. Berlin: Springer; 2001:403-411.
6. English J, Aldridge R, Gawkrodger DJ, et al. Consensus statement on the management of chronic hand eczema. Clin Exp Dermatol. 2009;34(7):761-769.
7. Coenraads PJ. Hand eczema is common and multifactorial. J Invest Dermatol. 2007;127(7):1568-1570.
8. Lerbaek A, Kyvik KO, Ravn H, Menne T, Agner T. Incidence of hand eczema in a population-based twin cohort: genetic and environmental risk factors. Br J Dermatol. 2007;157(3):552-557.
9. Skoet R, Olsen J, Mathiesen B, Iversen L, Johansen JD, Agner T. A survey of occupational hand eczema in Denmark. Contact Dermatitis. 2004;51(4):159-166.
10. Cvetkovski RS, Rothman KJ, Olsen J, et al. Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. Br J Dermatol. 2005;152(1):93-98.
11. Cvetkovski RS, Zachariae R, Jensen H, Olsen J, Johansen JD, Agner T. Quality of life and depression in a population of occupational hand eczema patients. Contact Dermatitis. 2006;54(2):106-111.
12. Agner T, Andersen KE, Brandao FM, et al. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis. 2008;59(1):43-47.
13. Kucharekova M, Van De Kerkhof PC, Van Der Valk PG. A randomized comparison of an emollient containing skin-related lipids with a petrolatum-based emollient as adjunct in the treatment of chronic hand dermatitis. Contact Dermatitis. 2003;48(6):293-299.
14. Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. J Drugs Dermatol. 2009;8(12):1093-1105.
15. Feldman S. Tachyphylaxis to topical corticosteroids: the more you use them, the less they work? Clin Dermatol. 2006;24(3):229-230.
16. Sjovall P, Christensen OB. Local and systemic effect of UVB irradiation in patients with chronic hand eczema. Acta Derm Venereol. 1987;67(6):538-541.
17. Polderman MC, Govaert JC, le Cessie S, Pavel S. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol. 2003;28(6):584-587.
18. Warshaw EM. Therapeutic options for chronic hand dermatitis. Dermatol Ther. 2004;17(3):240-250.
19. Van Coevorden AM, Coenraads PJ, Svensson A, et al. Overview of studies of treatments for hand eczema-the EDEN hand eczema survey. Br J Dermatol. 2004;151(2):446-451.
20. Moro JR, Iwata M, von Andriano UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. Sep 2008;8(9):685-698.
21. Scheinfeld N, Michaels J, Serradell N, et al. Aletretinonin. Retinoid, treatment of chromic hand dermatitis. Drugs Future. 2007;32(11):943-951.
22. Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev. 2006;58(4): 760-772.
23. Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev. 2006;58(4): 712-725.
24. Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. Expert Opin Investig Drugs. 2008;17(3):437-443.
25. Bollag W, Ott F. Successful treatment of chronic hand eczema with oral 9-cis-retinoic acid. Dermatology. 1999;199(4):308-312.
26. Ritchie HE, Brown-Woodman PD, Korabelnikoff A. Effect of co-administration of retinoids on rat embryo development in vitro. Birth Defects Res A Clin Mol Teratol. 2003;67(6):444-451.
27. Bonofiglio D, Cione E, Qi H, et al. Combined low doses of PPAR gamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol. 2009;175(3):1270-1280.
28. Xu J, Drew PD. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J Neuroimmunol. 2006;171(1-2):135-144.
29. Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS. 2002; 16(3):421-429.
30. Aboulafia DM, Norris D, Henry D, et al. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch Dermatol. 2003;139(2):178-186.
31. Munetsuna E, Hojo Y, Hattori M, et al. Retinoic acid stimulates 17beta-estradiol and testosterone synthesis in rat hippocampal slice cultures. Endocrinology. 2009;150(9):4260-4269.
32. Shen H, Luo Y, Kuo CC, et al. 9-Cis-retinoic acid reduces ischemic brain injury in rodents via bone morphogenetic protein. J Neurosci Res. 2009;87(2):545-555.
33. Grahovac M, Molin S, Prinz JC, Ruzicka T, Wollenberg A. Treatment of atopic eczema with oral alitretinoin. Br J Dermatol. 2009 Nov 3. [Epub ahead of print].
34. Molin S, Ruzicka T. Possible benefit of oral alitretinoin in T-lymphoproliferative diseases: a report of two patients with palmoplan-tar hyperkeratotic-rhagadiform skin changes and mycosis fungoides or Sezary syndrome. Br J Dermatol. 2009;161(6):1420-1422.
35. Ruzicka T, Larsen FG, Galewicz D, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol. 2004;140(12):1453-1459.
36. Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158(4):808-817.
37. Bissonnette R, Worm M, Gerlach B, et al. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. Br J Dermatol. 2009 Nov 10. [Epub ahead of print].
38. Fowler JF, Ghosh A, Sung J, et al. Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. J Am Acad Dermatol. 2006;54(3):448-457.
39. Blome C, Maares J, Diepgen T, Jeffrustenbach S, Augustin M. Measurement of patient-relevant benefits in the treatment of chronic hand eczema - a novel approach. Contact Dermatitis. 2009;61(1): 39-45.
40. English J. Alitretinoin (Toctino): new oral retinoid for chronic hand eczema. Prescriber. 2009:20(1):29-32.
41. Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: A NICE single technology appraisal. Pharmacoeconomics. 2010 Feb 4. [Epub ahead of print].